We provide professional support in Transtorasic fine needle biopsies.
Transthoracic fine needle aspiration biopsy (TTIIB) has
long been used to diagnose diseases in the lung. Advances in imaging
technology and cytopathology have improved the diagnostic power, accuracy,
safety and effectiveness of TTIIB. TTIIB is minimally invasive, making it
a powerful alternative to surgical interventions such as bronchoscopy,
mediastinoscopy or Endothoracic biopsy.
The diagnostic accuracy of benign and malignant diseases
with this method varies between 77-97%. The increasing use of TTIIB
(CT-TTIIB) accompanied by Computed Tomigraphy (CT) has reduced the need for
relatively more invasive surgeries such as thoracotomy and bronchoscopy.
Indications TTIIB is mostly used to evaluate pulmonary masses or
nodules. Lung parenchyma, mediastinal, hilar, pleural and chest wall
lesions can be diagnosed with TTIIB.
The advantages of ultrasound-guided TTIIB biopsy are that
it provides simultaneous imaging, enables us to detect nonvascular and
non-necrotic areas of the masses, and does not contain radiation. Masses
in the anterior mediastinum and peripheral lung masses adjacent to the costal
pleural surface are difficult to visualize on ultrasound, but can be detected
BT-TTIIB is the most widely used method . The advantage of
CT-guided TTIIB is that it can take excellent images. The advantage of
this method is that it provides a high diagnostic rate since we can see the
biopsy needle. However, there are disadvantages such as the lack of
real-time visualization, more procedure cost, more patient discomfort, and a
higher incidence of pneumothorax.